Pharmaceutical Technology on MSN2d
FDA grants orphan drug status to Arbor Biotechnologies’ PH1
The FDA has granted orphan drug designation (ODD) and RPDD to Arbor Biotechnologies' ABO-101, to treat primary hyperoxaluria ...
Kaleido Scope26d
UAB named OHF Care Center for excellence in rare kidney stone disease research and clinical care
Primary hyperoxaluria is a significant kidney stone disease caused by the overproduction of the molecule oxalate. It can be diagnosed as primary hyperoxaluria type one, two or three, with type one ...
BioWorld2d
Arbor’s ABO-101 awarded US orphan drug designation for primary hyperoxaluria type 1
Arbor Biotechnologies Inc.’s ABO-101 has been awarded orphan drug and rare pediatric disease designations by the FDA for the treatment of primary hyperoxaluria type 1 (PH1).